The Molbio Diagnostics IPO has entered its second day of bidding on a strong note, with investors showing keen interest and the grey market sending a positive signal. The point-of-care molecular diagnostics company currently commands a 17% grey market premium (GMP), up from 15% earlier, pointing to expectations of a strong debut on the stock exchanges.
The IPO was subscribed 83% on the first day, with investors bidding for a substantial portion of the 81.58 lakh shares on offer. Retail investors subscribed to 77% of the 40.69 lakh shares reserved for them, indicating steady participation from individual investors.
